Med Student Medical News about Complex Regional Pain Syndromes Ketamine Infusions, Intravenous

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study
Pain, 09/25/09

Schwartzman RJ et al. – The results of this study warrant a larger randomized placebo controlled trial using higher doses of ketamine and a longer follow–up period.

Methods

Randomized double–blind placebo controlled trial.
Before treatment, after informed consent was obtained, each subject was randomized into a ketamine or a placebo infusion group.
Study subjects were evaluated for at least 2 weeks prior to treatment and for 3 months following treatment.
All subjects were infused intravenously with normal saline with or without ketamine for 4 h (25 ml/h) daily for 10 days. The maximum ketamine infusion rate was 0.35 mg/kg/h, not to exceed 25 mg/h over a 4 h period.
Subjects in both the ketamine and placebo groups were administered clonidine and versed.

Results

Intravenous ketamine administered in an outpatient setting resulted in statistically significant reductions in many pain parameters.
Subjects in the placebo group demonstrated no treatment effect in any parameter.

<< Previous
Genomic assessment of follicular marker genes as pregnancy...

Next >>
Effects of tissue age, presence of neurones and endothelin-3 on...